Cargando…

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis

BACKGROUND/AIMS: To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP). METHODS: A systematic literature review adapted from the Li et al (Oph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harasymowycz, Paul, Royer, Catherine, Cui, Amy Xianying, Barbeau, Martin, Jobin-Gervais, Katherine, Mathurin, Karine, Lachaine, Jean, Beauchemin, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046749/ https://www.ncbi.nlm.nih.gov/pubmed/33397657 http://dx.doi.org/10.1136/bjophthalmol-2020-317262

Ejemplares similares

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis
por: Lo, Tzu-Chen, et al.
Publicado: (2022)

Critical evaluation of latanoprostene bunod in the treatment of glaucoma
por: Garcia, Giancarlo A, et al.
Publicado: (2016)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma
por: Zhou, Benjamin, et al.
Publicado: (2022)

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019)

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
por: Weinreb, Robert N, et al.
Publicado: (2015)

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
por: Kawase, Kazuhide, et al.
Publicado: (2016)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis, Victoria M, et al.
Publicado: (2018)

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma
por: Okeke, Constance O., et al.
Publicado: (2020)

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
por: Wang, Yulong, et al.
Publicado: (2020)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
por: Araie, Makoto, et al.
Publicado: (2015)

Comparison of Newly Diagnosed Ocular Hypertension and Open-Angle Glaucoma: Ocular Variables, Risk Factors, and Disease Severity
por: Buys, Yvonne M., et al.
Publicado: (2012)

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
por: Lachaine, Jean, et al.
Publicado: (2014)

Travoprost in the management of open-angle glaucoma and ocular hypertension
por: Denis, Philippe, et al.
Publicado: (2007)

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review
por: Hillhouse, Erin, et al.
Publicado: (2021)

Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
por: Schultz, Clyde
Publicado: (2011)

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
por: Harasymowycz, Paul, et al.
Publicado: (2021)

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016)

Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
por: Cantor, Erika, et al.
Publicado: (2018)

Selective Laser Trabeculoplasty in the Treatment of Ocular Hypertension and Open-Angle Glaucoma: Clinical Review
por: Zgryźniak, Aleksandra, et al.
Publicado: (2021)

The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma
por: Meda, Roman, et al.
Publicado: (2017)

Corneal Biomechanics for Ocular Hypertension, Primary Open-Angle Glaucoma, and Amyloidotic Glaucoma: A Comparative Study by Corvis ST
por: Silva, Nisa, et al.
Publicado: (2022)

Short-Term Reproducibility of Twenty-Four-Hour Intraocular Pressure Curves in Untreated Patients with Primary Open-Angle Glaucoma and Ocular Hypertension
por: Xu, Shuo, et al.
Publicado: (2015)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Pozarowska, Dorota
Publicado: (2010)

Outcome of Selective Laser Trabeculoplasty in Young Patients with Primary Open-Angle Glaucoma and Ocular Hypertension
por: Liu, Dan, et al.
Publicado: (2020)

MLIP genotype as a predictor of pharmacological response in primary open-angle glaucoma and ocular hypertension
por: Canut, María I., et al.
Publicado: (2021)

Comparison of Iridocorneal Angle Assessments in Open-Angle Glaucoma and Ocular Hypertension Patients: Anterior Segment Optical Coherence Tomography and Gonioscopy
por: Craven, E Randy, et al.
Publicado: (2022)

Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results
por: Salimi, Ali, et al.
Publicado: (2021)

Brimonidine in the treatment of glaucoma and ocular hypertension
por: Cantor, Louis B
Publicado: (2006)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
por: Syed, Misha F, et al.
Publicado: (2011)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
por: Aihara, Makoto
Publicado: (2010)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Mirza, Sophia K, et al.
Publicado: (2010)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Teus, Miguel A, et al.
Publicado: (2009)

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension
por: Gandolfi, Stefano A., et al.
Publicado: (2014)

Spectral analysis of intraocular pressure pulse wave in ocular hypertensive and primary open angle glaucoma patients
por: Bozic, Marija M, et al.
Publicado: (2016)

Corneal biomechanics and biomechanically corrected intraocular pressure in primary open-angle glaucoma, ocular hypertension and controls
por: Vinciguerra, Riccardo, et al.
Publicado: (2020)

Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Medeiros, Felipe A., et al.
Publicado: (2022)

Impact of Systemic Comorbidities on Ocular Hypertension and Open-Angle Glaucoma, in a Population from Spain and Portugal
por: Garcia-Villanueva, Carolina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8qs4i2iktdtmtmuknfg1s601vo